{"id":14411,"date":"2011-02-01T10:23:22","date_gmt":"2011-02-01T10:23:22","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=14411"},"modified":"2011-02-01T10:23:22","modified_gmt":"2011-02-01T10:23:22","slug":"darunavir-once-daily-indication-in-treatment-experienced-adults","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/14411","title":{"rendered":"Darunavir once-daily indication in treatment experienced adults"},"content":{"rendered":"<p>On 13 December 2010, FDA approved new labeling for darunavir (Prezista) to include a once-daily dosing for treatment-experienced adult patients who have no darunavir-associated resistance mutations.<\/p>\n<p>Darunavir-associated mutations are V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V and L89V.<\/p>\n<p>For patients without darunavir-associated mutations the dose is 800 mg darunavir once daily with ritonavir 100 mg once daily and with food.<\/p>\n<p>For patients with one or more darunavir-associated mutations* the indication remains 600 mg darunavir twice-daily taken with ritonavir 100 mg twice-daily and with food.<\/p>\n<p>Adverse reactions (Section 6.3) was modified to include neutropenia, lipoatrophy, and lipodystrophy under Postmarketing Events in the package inserts.<\/p>\n<p>For details of other changes, please refer to the full prescribing labeling:<a href=\"http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm\"><br \/>\nhttp:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>On 13 December 2010, FDA approved new labeling for darunavir (Prezista) to include a once-daily dosing for treatment-experienced adult patients who have no darunavir-associated resistance mutations. Darunavir-associated mutations are V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V and &hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-14411","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/14411","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=14411"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/14411\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=14411"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=14411"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=14411"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}